PEPFAR has long enjoyed bipartisan support on the Hill. Yet, it has not been spared from significant cuts in President Trump’s latest budget request for foreign aid. It is noteworthy that this administration’s three successive budget requests have proposed increasingly large cuts to PEPFAR’s funding. If past is prelude, a cut of this magnitude is unlikely to materialize in any final spending bill.
CGD Policy Blogs
Last fall, policymakers gathered in Astana, Kazakhstan to renew their commitment to primary health care (PHC). The gathering marked the 40th anniversary of the landmark Declaration of Alma-Ata, which enshrined health as a basic human right and paved the way for global recognition of PHC as a fundamental component of national health systems.
Last month, 3,500 policymakers, practitioners, advocates, researchers, and youth delegates from around the globe descended upon Kigali for the 5th International Conference on Family Planning. In case you didn’t make it to Kigali, here are our key takeaways and the questions they raise.
“Better data drive better decisions” is a truism that researchers everywhere are all too familiar with. Increasing the availability, usability, and relevance of data is key to tracking performance and informing smarter, more efficient policies—but too often the data we need simply aren’t available, at least not in a useful format. Recently, we’ve been exploring the availability of data (or lack thereof) related to global health commodity markets in the context of CGD’s working group on the Future of Global Health Procurement. To ground the working group’s recommendations, we’re trying to understand the current state of health commodity procurement in low- and middle-income countries (LMICs)—specifically which commodities are procured, by whom, how, and at what price.
Building on Experience: Lessons about Family Planning from Four Former Directors of USAID’s Office of Population and Reproductive Health
Last month, CGD hosted four former directors of USAID’s Office of Population and Reproductive Health to reflect on their experiences, which spanned US administrations from Ronald Reagan to Barack Obama. (You can watch the event here). Below, we highlight three main takeaways— the critical role of technical leadership, the importance of data, and the need to start with the end in mind when planning for successful transitions.
What can we say about the relative size and composition of health commodity markets across different countries? We took a stab at piecing together publicly available data sources to find an initial answer for low- and middle-income countries as part of the background work to inform the CGD Working Group on the Future of Global Health Procurement.
McDonald's has just gone global with its commitment to serve chicken free from antibiotics that are critically important to human health. Building on a similar phase-out in its US chicken supply in 2016, the company will ban critical antibiotic use from sourced chicken in a handful of high-income countries and Brazil in 2018, expanding to a longer list of “designated markets” by 2027. That's evidence of both the potential to reduce global antibiotic use in livestock and the vital role consumers can play in speeding progress.
Taking Stock of Aid Agency Evaluations in Global Health: Here’s What We Know about Evaluation Quality and What Funders Can Do Better
With the US Congress considering cuts to foreign assistance and aid budgets in other donor countries coming under increased pressure, evidence about what works in global development is more important than ever. Evidence should inform decisions on where to allocate scarce resources—but to do so, evaluations must be of good quality.
Health products—including drugs, devices, diagnostics, and vector control tools—are essential for meeting the healthcare needs of any population. Right now, many low- and lower-middle-income countries rely on donor-managed mechanisms to procure a large share of these health commodities. But this status quo won’t stay static for long, and the global health community must prepare for sweeping changes in global health and procurement over the next 10–20 years. Here’s some of what we see happening now and on the immediate horizon.
Without global action, by 2050 there could be as many as 10 million antimicrobial resistance-related deaths each year. An important—and often overlooked—part of the problem is the overuse of antibiotics in farm animals. CGD recently convened a roundtable discussion with technical experts to discuss possible ways to strengthen global cooperation to address livestock’s contribution to AMR. Drawing on that productive discussion, we outline steps that could help make inroads into the problem.